Zipalertinib Combo Extends Lung Cancer Survival
A Phase 3 trial found adding zipalertinib to chemotherapy nearly doubled progression-free survival in untreated EGFR exon 20 lung cancer.
Updated on Nov. 6, 2026 in Cancer
Results from the Phase 3 REZILIENT3 trial, presented this fall, showed zipalertinib plus chemotherapy extended progression-free survival to 14.5 months versus 8.5 months with chemotherapy alone in nearly 300 randomized patients with EGFR exon 20 non-small cell lung cancer. A new drug application for zipalertinib monotherapy in the second-line setting has also been submitted to the FDA.
Why it matters
The trial mirrors the established strategy of pairing a targeted agent with chemotherapy, offering a potential first-line option for a difficult-to-treat lung cancer subtype. A regulatory decision on the monotherapy application is expected within the next couple of months.
The Phase 3 REZILIENT3 trial randomized nearly 300 patients, and progression-free survival was 14.5 months with the combination versus 8.5 months with chemotherapy (hazard ratio 0.5). Overall survival data remain immature, and 64% of chemotherapy-progressing patients crossed over to zipalertinib monotherapy.
The players
Zipalertinib
An investigational oral EGFR exon 20 inhibitor being developed for non-small cell lung cancer, which is the subject of both the combination trial and the monotherapy application.
U.S. Food and Drug Administration (FDA)
The U.S. federal agency responsible for reviewing the new drug application for zipalertinib monotherapy in the second-line setting.
The details
Patients with untreated brain metastases up to 2 cm were eligible and randomized 1:1 to zipalertinib plus chemotherapy or chemotherapy alone. The most frequent adverse events with the combination were anemia and thrombocytopenia, many grade 3 or higher, and pneumonitis appeared in 5.7% of treated patients.
Timeline
Phase 3 data were presented at the World Conference on Lung Cancer this fall.
An FDA decision on the zipalertinib monotherapy application is expected within the next couple of months.
Cancer Treatment Landscape
The REZILIENT3 design follows the established approach of adding a targeted agent to platinum-based chemotherapy, a strategy that has reshaped first-line care for other driver-mutated lung cancers. Its results would extend that model to EGFR exon 20 insertion mutations, a subtype that has historically responded poorly to standard therapy.
For patients with EGFR exon 20 lung cancer, a combination option could offer longer control of disease before progression than chemotherapy alone. Anyone considering treatment should discuss with their oncology team whether trial-based or newly approved options fit their situation.
The takeaway
Targeted additions to chemotherapy continue to show measurable gains in progression-free survival, though overall survival data will determine how durable those gains prove to be.
What happens next
An FDA decision on the zipalertinib monotherapy new drug application is expected within the next couple of months.
Further reading
Explore more in Cancer coverage.
Source note: This article includes information reported by Ajmc.
